Fisher & Paykel Healthcare Corporation Limited

NZSE:FPH Stock Report

Market Cap: NZ$20.6b

Fisher & Paykel Healthcare Valuation

Is FPH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of FPH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
NZ$24.84
Fair Value
41.5% overvalued intrinsic discount
11
Number of Analysts

Below Fair Value: FPH (NZ$35.15) is trading above our estimate of fair value (NZ$24.84)

Significantly Below Fair Value: FPH is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for FPH?

Key metric: As FPH is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for FPH. This is calculated by dividing FPH's market cap by their current earnings.
What is FPH's PE Ratio?
PE Ratio115.4x
EarningsNZ$178.50m
Market CapNZ$20.60b

Price to Earnings Ratio vs Peers

How does FPH's PE Ratio compare to its peers?

The above table shows the PE ratio for FPH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average31.9x
EBO EBOS Group
26.9x7.1%NZ$8.1b
SN. Smith & Nephew
35.5x19.8%UK£8.7b
BIM bioMérieux
32.5x13.6%€13.4b
6869 Sysmex
32.7x12.9%JP¥1.8t
FPH Fisher & Paykel Healthcare
115.4x23.9%NZ$20.6b

Price-To-Earnings vs Peers: FPH is expensive based on its Price-To-Earnings Ratio (115.4x) compared to the peer average (31.9x).

Price to Earnings Ratio vs Industry

How does FPH's PE Ratio compare vs other companies in the Global Medical Equipment Industry?

8 CompaniesPrice / EarningsEstimated GrowthMarket Cap
FPH 115.4xIndustry Avg. 26.9xNo. of Companies50PE020406080100+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: FPH is expensive based on its Price-To-Earnings Ratio (115.4x) compared to the Global Medical Equipment industry average (26.9x).

Price to Earnings Ratio vs Fair Ratio

What is FPH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

FPH PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio115.4x
Fair PE Ratio27.6x

Price-To-Earnings vs Fair Ratio: FPH is expensive based on its Price-To-Earnings Ratio (115.4x) compared to the estimated Fair Price-To-Earnings Ratio (27.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst FPH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentNZ$35.15
NZ$34.38
-2.2%
13.5%NZ$41.70NZ$25.00n/a11
Feb ’26NZ$37.60
NZ$34.87
-7.3%
13.7%NZ$41.70NZ$25.00n/a11
Jan ’26NZ$38.40
NZ$33.46
-12.9%
18.2%NZ$41.70NZ$20.14n/a12
Dec ’25NZ$38.05
NZ$33.46
-12.1%
18.2%NZ$41.70NZ$20.14n/a12
Nov ’25NZ$36.07
NZ$31.56
-12.5%
18.3%NZ$39.20NZ$20.14n/a12
Oct ’25NZ$34.99
NZ$31.56
-9.8%
18.3%NZ$39.20NZ$20.14n/a12
Sep ’25NZ$35.60
NZ$30.40
-14.6%
17.9%NZ$38.20NZ$20.14n/a12
Aug ’25NZ$32.85
NZ$26.11
-20.5%
12.3%NZ$32.80NZ$20.14n/a12
Jul ’25NZ$29.95
NZ$26.16
-12.6%
11.8%NZ$32.80NZ$20.14n/a13
Jun ’25NZ$29.50
NZ$26.16
-11.3%
11.8%NZ$32.80NZ$20.14n/a13
May ’25NZ$28.21
NZ$24.20
-14.2%
10.3%NZ$29.10NZ$18.40n/a13
Apr ’25NZ$25.65
NZ$23.97
-6.6%
9.8%NZ$28.50NZ$18.40n/a13
Mar ’25NZ$24.72
NZ$22.24
-10.0%
8.9%NZ$25.00NZ$18.40n/a13
Feb ’25NZ$23.95
NZ$22.14
-7.6%
9.0%NZ$25.00NZ$18.40NZ$37.6013
Jan ’25NZ$23.60
NZ$22.27
-5.6%
8.6%NZ$25.00NZ$18.40NZ$38.4013
Dec ’24NZ$23.81
NZ$22.27
-6.5%
8.6%NZ$25.00NZ$18.40NZ$38.0513
Nov ’24NZ$21.10
NZ$22.01
+4.3%
7.9%NZ$25.00NZ$19.45NZ$36.0711
Oct ’24NZ$21.58
NZ$22.27
+3.2%
6.9%NZ$25.00NZ$20.00NZ$34.9911
Sep ’24NZ$22.50
NZ$23.13
+2.8%
11.2%NZ$28.09NZ$20.00NZ$35.6011
Aug ’24NZ$24.60
NZ$23.55
-4.3%
12.0%NZ$28.09NZ$20.00NZ$32.8511
Jul ’24NZ$24.50
NZ$23.55
-3.9%
12.0%NZ$28.09NZ$20.00NZ$29.9511
Jun ’24NZ$24.38
NZ$23.55
-3.4%
12.0%NZ$28.09NZ$20.00NZ$29.5011
May ’24NZ$27.41
NZ$24.13
-12.0%
12.5%NZ$29.00NZ$20.00NZ$28.2111
Apr ’24NZ$26.65
NZ$24.03
-9.8%
12.1%NZ$29.00NZ$20.00NZ$25.6511
Mar ’24NZ$25.58
NZ$24.03
-6.1%
12.1%NZ$29.00NZ$20.00NZ$24.7211
Feb ’24NZ$25.92
NZ$24.03
-7.3%
12.1%NZ$29.00NZ$20.00NZ$23.9511
Analyst Price Target
Consensus Narrative from 11 Analysts
NZ$34.38
Fair Value
2.2% overvalued intrinsic discount
11
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/08 10:13
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Fisher & Paykel Healthcare Corporation Limited is covered by 27 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Russell WrightBarclay Pearce Capital Pty Limited
Saul HadassinBarrenjoey Markets Pty Limited
Lyanne HarrisonBofA Global Research